Shots:
Vanda Pharmaceuticals reported that its P-III (Study 3201 / VP-VQW-765-3201; NCT07221578) of VQW-765 for on-demand treatment of acute anxiety in adults with social anxiety disorder did not meet its 1EP
The multicenter, randomized, double-blind, placebo-controlled US study (n=546; ~30 sites) evaluated a single oral dose of VQW-765 vs PBO (1:1) ahead of the Trier…
